Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline

155 394

Cited 8 times in

Authors: Kyung-Jin Min ; Sang-Hoon Kwon ; Sunghoon Kim ; Hyun Jung Kim ; Seok Ju Seong ; Yong Jung Song ; Jin Woo Shin ; Keun-Ho Lee ; Myong Cheol Lim ; Hyun Hoon Chung ; Woong Ju ; Jin Hwa Hong ; Jeong-Won Lee ; Jae-Weon Kim ; Duk-Soo Bae ; Jae-Kwan Lee

MeSH: Adolescent ; Adult ; Age Factors ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/adverse effects ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Middle Aged ; Papillomavirus Vaccines/administration & dosage ; Papillomavirus Vaccines/adverse effects ; Papillomavirus Vaccines/therapeutic use* ; Practice Guidelines as Topic* ; Republic of Korea ; Treatment Outcome ; Uterine Cervical Neoplasms/prevention & control* ; Young Adult

Abstract: After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.